
Baptiste Hervier

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3059990/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Correspondence on â€~Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis'. Annals of the Rheumatic Diseases, 2022, 81, e241-e241.	0.9	10
2	Treatment strategies and safety of rechallenge in the setting of immune checkpoint inhibitors-related myositis: a national multicentre study. Rheumatology, 2021, 60, 5753-5764.	1.9	17
3	Increased Concentrations of Circulating Soluble MHC Class I-Related Chain A (sMICA) and sMICB and Modulation of Plasma Membrane MICA Expression: Potential Mechanisms and Correlation With Natural Killer Cell Activity in Systemic Lupus Erythematosus. Frontiers in Immunology, 2021, 12, 633658.	4.8	10
4	Anti-RNP antibodies delineate a subgroup of myositis: A systematic retrospective study on 46 patients. Autoimmunity Reviews, 2020, 19, 102465.	5.8	14
5	Relationship between change in physical activity and in clinical status in patients with idiopathic inflammatory myopathy: A prospective cohort study. Seminars in Arthritis and Rheumatism, 2020, 50, 1140-1149.	3.4	14
6	Different phenotypes in dermatomyositis associated with anti-MDA5 antibody. Neurology, 2020, 95, e70-e78.	1.1	142
7	Rituximab and Cyclophosphamide in Antisynthetase Syndrome–related Interstitial Lung Disease: An Observational Retrospective Study. Journal of Rheumatology, 2020, 47, 1678-1686.	2.0	18
8	Severe axial and pelvifemoral muscle damage in immune-mediated necrotizing myopathy evaluated by whole-body MRI. Seminars in Arthritis and Rheumatism, 2020, 50, 1437-1440.	3.4	28
9	NK Cells in the Human Lungs. Frontiers in Immunology, 2019, 10, 1263.	4.8	57
10	Juvenile temporal arteritis: A clinicopathological multicentric experience. Autoimmunity Reviews, 2019, 18, 476-483.	5.8	16
11	Rituximab in the Treatment of Refractory Anti-HMGCR Immune-mediated Necrotizing Myopathy. Journal of Rheumatology, 2019, 46, 623-627.	2.0	36
12	Management of immune-related adverse events resulting from immune checkpoint blockade. Expert Review of Anticancer Therapy, 2019, 19, 209-222.	2.4	20
13	Inflammatory Myopathy-Related Interstitial Lung Disease: From Pathophysiology to Treatment. Frontiers in Medicine, 2019, 6, 326.	2.6	43
14	Antisynthetase syndrome pathogenesis: knowledge and uncertainties. Current Opinion in Rheumatology, 2018, 30, 664-673.	4.3	52
15	Sarcoidosis in Patients with Antisynthetase Syndrome: Presentation and Outcome. Journal of Rheumatology, 2018, 45, 1296-1300.	2.0	5
16	Polyfunctionality of bona fide resident lung CD69 + natural killer cells. Journal of Allergy and Clinical Immunology, 2017, 140, 317-318.	2.9	4
17	Involvement of NK Cells and NKp30 Pathway in Antisynthetase Syndrome. Journal of Immunology, 2016, 197, 1621-1630.	0.8	26
18	Severe adult dermatomyositis with unusual calcinosis: Fig. 1. Rheumatology, 2015, 54, 2024-2024.	1.9	8

BAPTISTE HERVIER

#	Article	IF	CITATIONS
19	Clinical Heterogeneity and Outcomes of Antisynthetase Syndrome. Current Rheumatology Reports, 2013, 15, 349.	4.7	69
20	Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival. European Respiratory Journal, 2013, 42, 1271-1282.	6.7	108
21	Hierarchical cluster and survival analyses of antisynthetase syndrome: Phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmunity Reviews, 2012, 12, 210-217.	5.8	233
22	Antisynthetase Syndrome with Anti-Jo1 Antibodies in 48 Patients: Pulmonary Involvement Predicts Disease-modifying Antirheumatic Drug Use. Journal of Rheumatology, 2012, 39, 1835-1839.	2.0	48
23	Treatment of Erdheim-Chester Disease with Long-Term High-Dose Interferon-α. Seminars in Arthritis and Rheumatism, 2012, 41, 907-913.	3.4	83
24	CMV drives clonal expansion of NKG2C ⁺ NK cells expressing selfâ€specific KIRs in chronic hepatitis patients. European Journal of Immunology, 2012, 42, 447-457.	2.9	261
25	Phenotype and function of natural killer cells in systemic lupus erythematosus: Excess interferon-Î ³ production in patients with active disease. Arthritis and Rheumatism, 2011, 63, 1698-1706.	6.7	116
26	Anti-synthetase syndrome positive for anti-isoleucyl-tRNA synthetase antibodies: an unusual case overlapping with systemic sclerosis and Sjogren's syndrome. Rheumatology, 2011, 50, 1175-1176.	1.9	16
27	Clinical manifestations of anti-synthetase syndrome positive for anti-alanyl-tRNA synthetase (anti-PL12) antibodies: a retrospective study of 17 cases. Rheumatology, 2010, 49, 972-976.	1.9	75
28	Association of Langerhans Cell Histiocytosis with Erdheim-Chester Disease: How Close Monocyte/Macrophage and Dendritic Cell Lineages Are?. Blood, 2010, 116, 4716-4716.	1.4	0
29	Long-term efficacy of mycophenolate mofetil in a case of refractory antisynthetase syndrome. Joint Bone Spine, 2009, 76, 575-576.	1.6	37